Ivor Dropco, Ulrich Kaiser, Lola Wagner, Stefan M Brunner, Hans Jürgen Schlitt, Christian Stroszcynski, Friedrich Jung, Dong Yi, Wolfgang Herr, Ernst Michael Jung
Aims: To assess the value of using integrated parametric ultrasound software for contrast-enhanced ultrasonography (CEUS) of liver tumors.
Methods: 107 patients with liver tumors were studied. CEUS were performed to detect focal lesions. Parametric images were based on continuous CINE LOOPs, from the early-arterial phase (15 s) to the portal-venous phase (1 min) generated by perfusion software. The evaluations of the parametric images and their dignity for liver lesions were performed independently by an experienced and a less-experienced investigator. Computed tomography, magnetic resonance imaging scans or histological analysis were used as references.
Results: High parametric image quality were obtained in all patients. Among the patients, 44% lesions were benign, 56% were malignant. The experienced investigator correctly classified 46 of 47 (98%) as benign, and 60 of 60 (100%) as malignant tumors based on the parametric images. The less-experienced investigator correctly classified 39 of 47 (83%) as benign, and 49 of 60 (82%) malignant tumors, acheaving a high statistical accuracy of 98% with this type of diagnostic.
Conclusion: Parametric imaging for grading the malignant degree of tumor may be a good complement to existing ultrasound techniques and was particularly helpful for improving the assessments of the less-experienced examiner.
{"title":"Color Mapping using Ultrasound System-integrated Perfusion Software for Evaluation of Focal Liver Lesions: A Possible First Step for More Independent Reading.","authors":"Ivor Dropco, Ulrich Kaiser, Lola Wagner, Stefan M Brunner, Hans Jürgen Schlitt, Christian Stroszcynski, Friedrich Jung, Dong Yi, Wolfgang Herr, Ernst Michael Jung","doi":"10.15403/jgld-4997","DOIUrl":"10.15403/jgld-4997","url":null,"abstract":"<p><strong>Aims: </strong>To assess the value of using integrated parametric ultrasound software for contrast-enhanced ultrasonography (CEUS) of liver tumors.</p><p><strong>Methods: </strong>107 patients with liver tumors were studied. CEUS were performed to detect focal lesions. Parametric images were based on continuous CINE LOOPs, from the early-arterial phase (15 s) to the portal-venous phase (1 min) generated by perfusion software. The evaluations of the parametric images and their dignity for liver lesions were performed independently by an experienced and a less-experienced investigator. Computed tomography, magnetic resonance imaging scans or histological analysis were used as references.</p><p><strong>Results: </strong>High parametric image quality were obtained in all patients. Among the patients, 44% lesions were benign, 56% were malignant. The experienced investigator correctly classified 46 of 47 (98%) as benign, and 60 of 60 (100%) as malignant tumors based on the parametric images. The less-experienced investigator correctly classified 39 of 47 (83%) as benign, and 49 of 60 (82%) malignant tumors, acheaving a high statistical accuracy of 98% with this type of diagnostic.</p><p><strong>Conclusion: </strong>Parametric imaging for grading the malignant degree of tumor may be a good complement to existing ultrasound techniques and was particularly helpful for improving the assessments of the less-experienced examiner.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 4","pages":"479-487"},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply.","authors":"Francesco Di Mario","doi":"10.15403/jgld-5411","DOIUrl":"10.15403/jgld-5411","url":null,"abstract":"","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 4","pages":"559-560"},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Christian Sulz, Michael Doulberis, Nicolas Fournier, Luc Biedermann, Jonas Zeitz, Benjamin Misselwitz, Bruno Imthurn, Gerhard Rogler
Background and aims: Childlessness and infertility represent a frequent and important issue in inflammatory bowel disease (IBD) patients. Nevertheless, until now epidemiological data remains scarce. Therefore, main objectives of this study were to evaluate the rate of childlessness and the cumulative probability of reproduction in female and male IBD patients within the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS), a large prospective multicenter nationwide cohort.
Methods: Prospectively collected data of SIBDCS was used, comprising more than 3,300 patients with Crohn's disease (CD) and ulcerative colitis (UC). We analyzed the following groups of patients: 1) female IBD patients aged ≥40 years and diagnosed before age of 30 years with at least one follow-up, 2) female IBD patients who reported actively trying to conceive, with IBD diagnosed <35 years and with age at enrolment <45 years (longitudinal observation), with at least one follow-up, and 3) childless males who actively tried to conceive.
Results: A total of 1,412 female patients from the SIBDCS [843 CD, 539 UC, 30 indeterminate colitis (IC)] with available data were included in our analyses. Out of those 184 females (70.1% CD and 29.9 % UC) were aged ≥ 40 years and have been diagnosed with IBD before the age of 30 years. Among these, 184 women 32.1% were childless. The portion of childless females (36.4%) was significantly higher in CD vs. UC (36.4% vs. 21.8%; p=0.026), equaling a relative risk of childlessness of 1.7 in CD vs. UC. and higher than in the Swiss general population (21%). The mean number of children per female patient was 1.32 (median 1, min 0, max 6), per female with CD 1.12 (median 1, min 0, max 4), per female with UC/IC 1.78 (median 2, min 0, max 6; P=0.001). The longitudinal analysis of female IBD patients trying to conceive revealed that one out of two women neither were pregnant nor had born a child five years after first trying to conceive.
Conclusions: The rate of childlessness in females with CD is higher compared to the general Swiss population, whereas it is similar in women with UC. Moreover, the mean number of children is lower in CD than in UC. Females with CD remain more often childless compared to their UC counterparts. Although the exact underlying mechanisms are largely unknown, this discrepancy should alert healthcare professionals treating CD patients to actively address this topic.
{"title":"Childlessness in Patients with Inflammatory Bowel Disease - Data from the Prospective Multi-center Swiss IBD Cohort Study.","authors":"Michael Christian Sulz, Michael Doulberis, Nicolas Fournier, Luc Biedermann, Jonas Zeitz, Benjamin Misselwitz, Bruno Imthurn, Gerhard Rogler","doi":"10.15403/jgld-5132","DOIUrl":"10.15403/jgld-5132","url":null,"abstract":"<p><strong>Background and aims: </strong>Childlessness and infertility represent a frequent and important issue in inflammatory bowel disease (IBD) patients. Nevertheless, until now epidemiological data remains scarce. Therefore, main objectives of this study were to evaluate the rate of childlessness and the cumulative probability of reproduction in female and male IBD patients within the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS), a large prospective multicenter nationwide cohort.</p><p><strong>Methods: </strong>Prospectively collected data of SIBDCS was used, comprising more than 3,300 patients with Crohn's disease (CD) and ulcerative colitis (UC). We analyzed the following groups of patients: 1) female IBD patients aged ≥40 years and diagnosed before age of 30 years with at least one follow-up, 2) female IBD patients who reported actively trying to conceive, with IBD diagnosed <35 years and with age at enrolment <45 years (longitudinal observation), with at least one follow-up, and 3) childless males who actively tried to conceive.</p><p><strong>Results: </strong>A total of 1,412 female patients from the SIBDCS [843 CD, 539 UC, 30 indeterminate colitis (IC)] with available data were included in our analyses. Out of those 184 females (70.1% CD and 29.9 % UC) were aged ≥ 40 years and have been diagnosed with IBD before the age of 30 years. Among these, 184 women 32.1% were childless. The portion of childless females (36.4%) was significantly higher in CD vs. UC (36.4% vs. 21.8%; p=0.026), equaling a relative risk of childlessness of 1.7 in CD vs. UC. and higher than in the Swiss general population (21%). The mean number of children per female patient was 1.32 (median 1, min 0, max 6), per female with CD 1.12 (median 1, min 0, max 4), per female with UC/IC 1.78 (median 2, min 0, max 6; P=0.001). The longitudinal analysis of female IBD patients trying to conceive revealed that one out of two women neither were pregnant nor had born a child five years after first trying to conceive.</p><p><strong>Conclusions: </strong>The rate of childlessness in females with CD is higher compared to the general Swiss population, whereas it is similar in women with UC. Moreover, the mean number of children is lower in CD than in UC. Females with CD remain more often childless compared to their UC counterparts. Although the exact underlying mechanisms are largely unknown, this discrepancy should alert healthcare professionals treating CD patients to actively address this topic.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 4","pages":"460-468"},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We read with interest Affendi et al. [1] report about a patient with severe ulcerative colitis who responded to an accelerated dose of ustekinumab. We have the following comments and concerns. The patient‘s endoscopic images do not show the typical Mayo score 3 appearances of colitis. Severe ulcerative colitis is characterized by diffuse, circumferentially affected, granular mucosa with superficial ulcerations that may coalesce. Figures from the case show discrete, deep, oval ulcers. Furthermore, it almost has a cobblestone appearance, more specific to Crohn‘s disease [2]. In addition to colon involvement in Fig. 1A, the small intestinal loops (possible ileal segments) are thickened and edematous in the right lower quadrant, distant from the cecum. There is also the appearance of fat stranding. In ulcerative colitis, involvement of intestinal segments distant from the cecum is not expected, being specific to Crohn‘s disease [3]. Due to the severity of the disease, a pancolonoscopy could not be performed; therefore, disease extension was described using computed tomography. Not exceeding splenic flexure, it was interpreted as left-sided colitis. According to his medical history, 3 grams of mesalazine was started three weeks prior to his admission. Mesalazine >2.4 g/dL enteral and 1-gram topical forms are recommended by the 2017 ECCO (European Crohn‘s and Colitis Organisation) guideline for left-sided ulcerative colitis. The remission induction rate at this dose is high when compared to placebo [4]. If the patient has left-sided ulcerative colitis, we anticipate a positive response to a sufficient dose of 5-acetylsalicylic acid preparation. Finally, the histopathological findings are not mentioned in the article. Although there are no pathognomonic features specific to ulcerative colitis, the presence of granulomas (which can be found in 15-36% of mucosal biopsies) could indicate Crohn‘s disease [4, 5]. LETTERS TO THE EDITOR
{"title":"Accelerated dose of ustekinumab for acute severe ulcerative colitis.","authors":"İdris Kurt","doi":"10.15403/jgld-4825","DOIUrl":"10.15403/jgld-4825","url":null,"abstract":"We read with interest Affendi et al. [1] report about a patient with severe ulcerative colitis who responded to an accelerated dose of ustekinumab. We have the following comments and concerns. The patient‘s endoscopic images do not show the typical Mayo score 3 appearances of colitis. Severe ulcerative colitis is characterized by diffuse, circumferentially affected, granular mucosa with superficial ulcerations that may coalesce. Figures from the case show discrete, deep, oval ulcers. Furthermore, it almost has a cobblestone appearance, more specific to Crohn‘s disease [2]. In addition to colon involvement in Fig. 1A, the small intestinal loops (possible ileal segments) are thickened and edematous in the right lower quadrant, distant from the cecum. There is also the appearance of fat stranding. In ulcerative colitis, involvement of intestinal segments distant from the cecum is not expected, being specific to Crohn‘s disease [3]. Due to the severity of the disease, a pancolonoscopy could not be performed; therefore, disease extension was described using computed tomography. Not exceeding splenic flexure, it was interpreted as left-sided colitis. According to his medical history, 3 grams of mesalazine was started three weeks prior to his admission. Mesalazine >2.4 g/dL enteral and 1-gram topical forms are recommended by the 2017 ECCO (European Crohn‘s and Colitis Organisation) guideline for left-sided ulcerative colitis. The remission induction rate at this dose is high when compared to placebo [4]. If the patient has left-sided ulcerative colitis, we anticipate a positive response to a sufficient dose of 5-acetylsalicylic acid preparation. Finally, the histopathological findings are not mentioned in the article. Although there are no pathognomonic features specific to ulcerative colitis, the presence of granulomas (which can be found in 15-36% of mucosal biopsies) could indicate Crohn‘s disease [4, 5]. LETTERS TO THE EDITOR","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"411"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41151135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hoi Shan Cheung, Lok Yee Lu, Wang Leong So, Ho Wai Wong, Sei Hei Wong, Chloe Miu Mak
Background and aims: Colorectal cancer has the third highest incidence and second highest mortality among all cancers worldwide. Although numerous studies investigating the associations between high red meat intake and risk of colorectal cancer have been published, the association between the intake of red meat and the risk of colorectal cancer in Asians remains unclear. We performed a systematic review and meta-analysis of cohort and case-control studies to estimate the association between red meat intake and colorectal cancer incidence rate between 2011-2021.
Method: We searched PubMed database from 1 Jan 2011 to 21 July 2021. Prospective cohort studies and nested case-control studies that reported results on the association between red meat consumption and colorectal cancer were included in the meta-analysis. The outcome of interest was the association between the intake of red meat and the risk of colorectal cancer. We performed a meta-analysis to calculate the odds ratios (OR) with 95% confidence intervals (CI).
Results: A total of 5 studies enrolling 48,158 participants were included. The results showed no significant association between red meat intake and colorectal cancer risks (OR=1.38; 95%CI: 0.98-1.93). The aspect of the corresponding funnel plot suggested the presence of significant publication bias. Egger's test confirmed the significant asymmetry of the funnel plot (t = 9.3024, p = 0.0026).
Conclusions: Contrary to many other meta-analyses, our study showed that intake of red meat was not associated with increased risk of colorectal cancer in East-Asians from China, Japan and South Korea. However, due to the limited number of included papers and the lack of confounders adjustments, our results warrant cautious interpretations.
{"title":"Association of Red Meat Intake and Colorectal Cancer among East-Asians: A Systematic Review and Meta-analysis of Observational Studies Performed between 2011-2021.","authors":"Hoi Shan Cheung, Lok Yee Lu, Wang Leong So, Ho Wai Wong, Sei Hei Wong, Chloe Miu Mak","doi":"10.15403/jgld-4778","DOIUrl":"https://doi.org/10.15403/jgld-4778","url":null,"abstract":"<p><strong>Background and aims: </strong>Colorectal cancer has the third highest incidence and second highest mortality among all cancers worldwide. Although numerous studies investigating the associations between high red meat intake and risk of colorectal cancer have been published, the association between the intake of red meat and the risk of colorectal cancer in Asians remains unclear. We performed a systematic review and meta-analysis of cohort and case-control studies to estimate the association between red meat intake and colorectal cancer incidence rate between 2011-2021.</p><p><strong>Method: </strong>We searched PubMed database from 1 Jan 2011 to 21 July 2021. Prospective cohort studies and nested case-control studies that reported results on the association between red meat consumption and colorectal cancer were included in the meta-analysis. The outcome of interest was the association between the intake of red meat and the risk of colorectal cancer. We performed a meta-analysis to calculate the odds ratios (OR) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>A total of 5 studies enrolling 48,158 participants were included. The results showed no significant association between red meat intake and colorectal cancer risks (OR=1.38; 95%CI: 0.98-1.93). The aspect of the corresponding funnel plot suggested the presence of significant publication bias. Egger's test confirmed the significant asymmetry of the funnel plot (t = 9.3024, p = 0.0026).</p><p><strong>Conclusions: </strong>Contrary to many other meta-analyses, our study showed that intake of red meat was not associated with increased risk of colorectal cancer in East-Asians from China, Japan and South Korea. However, due to the limited number of included papers and the lack of confounders adjustments, our results warrant cautious interpretations.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"377-383"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Maria Garcia-Cabrera, Fernando De la Portilla, Rosa María Jiménez-Rodríguez, Jorge Manuel Vázquez-Monchul, María Luisa Reyes-Díaz, Irene María Ramallo-Solís, José Pintor-Tortolero, Sandra Dios-Barbeito, Francisco Javier Padillo-Ruiz
Background and aims: Irritable bowel syndrome (IBS) is a prevalent disorder with a complex and heterogeneous physiopathology, including a dysregulation of gut-brain axis. Treatment for IBS is targeted to the predominant symptom and requires a multidisciplinary approach. This review aims to evaluate the efficacy and safety of sacral nerve stimulation in non-constipated IBS patients Methods: A literature search was carried out on MEDLINE, The Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science databases for all relevant articles. Quality of included papers was assessed using standardized guidelines Results: Of 129 initial citations, 7 articles met our predefined inclusion criteria, including five randomized trials, a pilot study and a descriptive follow-up study. Five of 7 studies reported a positive effect of sacral nerve stimulation on symptoms and quality of life improvement in non-constipated IBS patients. No study reported serious adverse events.
Conclusions: Despite initial promising results of sacral nerve stimulation in non-constipated IBS patients, studies with larger sample sizes and longer follow-up are required.
背景和目的:肠易激综合征(IBS)是一种常见的疾病,具有复杂和异质的病理生理学,包括肠脑轴失调。IBS的治疗针对主要症状,需要多学科的方法。本综述旨在评估骶神经刺激治疗非便秘型肠易激综合征患者的有效性和安全性。方法:在MEDLINE、Cochrane对照试验中央登记册(Central)和Web of Science数据库中检索所有相关文章。纳入论文的质量使用标准化指南进行评估结果:在129篇首次引用中,有7篇文章符合我们预定义的纳入标准,包括5项随机试验、一项试点研究和一项描述性随访研究。7项研究中有5项报告了骶神经刺激对非便秘IBS患者症状和生活质量改善的积极影响。没有研究报告严重不良事件。结论:尽管骶神经刺激治疗非便秘型肠易激综合征患者的初步结果很有希望,但仍需要更大样本量和更长随访时间的研究。
{"title":"Efficacy of Sacral Nerve Stimulation in Non-constipated Irritable Bowel Syndrome Patients: A Systematic Review.","authors":"Ana Maria Garcia-Cabrera, Fernando De la Portilla, Rosa María Jiménez-Rodríguez, Jorge Manuel Vázquez-Monchul, María Luisa Reyes-Díaz, Irene María Ramallo-Solís, José Pintor-Tortolero, Sandra Dios-Barbeito, Francisco Javier Padillo-Ruiz","doi":"10.15403/jgld-4801","DOIUrl":"10.15403/jgld-4801","url":null,"abstract":"<p><strong>Background and aims: </strong>Irritable bowel syndrome (IBS) is a prevalent disorder with a complex and heterogeneous physiopathology, including a dysregulation of gut-brain axis. Treatment for IBS is targeted to the predominant symptom and requires a multidisciplinary approach. This review aims to evaluate the efficacy and safety of sacral nerve stimulation in non-constipated IBS patients Methods: A literature search was carried out on MEDLINE, The Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science databases for all relevant articles. Quality of included papers was assessed using standardized guidelines Results: Of 129 initial citations, 7 articles met our predefined inclusion criteria, including five randomized trials, a pilot study and a descriptive follow-up study. Five of 7 studies reported a positive effect of sacral nerve stimulation on symptoms and quality of life improvement in non-constipated IBS patients. No study reported serious adverse events.</p><p><strong>Conclusions: </strong>Despite initial promising results of sacral nerve stimulation in non-constipated IBS patients, studies with larger sample sizes and longer follow-up are required.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"384-392"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and aims: Currently malignancies of the liver are the sixth most frequently diagnosed cancers worldwide. The admission of patients to hospitals decreased due to the restriction of the Coronavirus disease 2019 (COVİD-19) pandemic, especially patients suspected with cancer were delayed in their diagnosis and treatment. With this study, we aimed to investigate whether the Covid-19 pandemic caused a decrease in the number of hepatocellular cancers (HCC) or a delay in its diagnosis.
Methods: The study, which included newly diagnosed HCC patients, was conducted as a retrospective cross sectional study, in a single Turkey medical center. The patients were divided into pre-COVID-19 and post- COVID-19 two-year periods and compared in terms of tumor size, biochemical parameters, clinical and demographic features.
Results: A total of 63 HCC patients, 46 (73%) patients before the COVID-19 pandemic and 17 (27%) patients diagnosed during the COVID-19 pandemic were included. Maximum diameter of lesions and serum alpha- fetoprotein levels showed a statistically significant difference between the groups. Maximum tumor size in the pre-COVID-19 period was 4.58±3.77 mm, while in the COVID-19 period was 7.42±6.88 mm, the difference between two groups being statistically significant (p<0.05). HCC in the pre-COVID-19 period were detected mostly at Barcelona Clinic for Liver Cancer (BCLC) stage A (45.7%, n=21), while in the COVID-19 period most of HCC were detected at stage B (35.3%, n=6).
Conclusions: The COVID-19 pandemic limited the access of patients to screening programs for HCC. The significant disruption in screening cirrhotic patients for HCC has led to a delay in diagnosis.
{"title":"Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Single Turkey Center Study.","authors":"Gülden Bilican, Seçkin Özgül, Nergiz Ekmen, Kenan Moral, Harun Küçük, Serkan Dumanlı, Azer Abiyev, Tarkan Karakan, Murat Kekilli","doi":"10.15403/jgld-4821","DOIUrl":"https://doi.org/10.15403/jgld-4821","url":null,"abstract":"<p><strong>Background and aims: </strong>Currently malignancies of the liver are the sixth most frequently diagnosed cancers worldwide. The admission of patients to hospitals decreased due to the restriction of the Coronavirus disease 2019 (COVİD-19) pandemic, especially patients suspected with cancer were delayed in their diagnosis and treatment. With this study, we aimed to investigate whether the Covid-19 pandemic caused a decrease in the number of hepatocellular cancers (HCC) or a delay in its diagnosis.</p><p><strong>Methods: </strong>The study, which included newly diagnosed HCC patients, was conducted as a retrospective cross sectional study, in a single Turkey medical center. The patients were divided into pre-COVID-19 and post- COVID-19 two-year periods and compared in terms of tumor size, biochemical parameters, clinical and demographic features.</p><p><strong>Results: </strong>A total of 63 HCC patients, 46 (73%) patients before the COVID-19 pandemic and 17 (27%) patients diagnosed during the COVID-19 pandemic were included. Maximum diameter of lesions and serum alpha- fetoprotein levels showed a statistically significant difference between the groups. Maximum tumor size in the pre-COVID-19 period was 4.58±3.77 mm, while in the COVID-19 period was 7.42±6.88 mm, the difference between two groups being statistically significant (p<0.05). HCC in the pre-COVID-19 period were detected mostly at Barcelona Clinic for Liver Cancer (BCLC) stage A (45.7%, n=21), while in the COVID-19 period most of HCC were detected at stage B (35.3%, n=6).</p><p><strong>Conclusions: </strong>The COVID-19 pandemic limited the access of patients to screening programs for HCC. The significant disruption in screening cirrhotic patients for HCC has led to a delay in diagnosis.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"32 3","pages":"367-370"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}